2024 – The Year of Production | Highlights from the AWS Life Sciences Leaders Symposium 2024

The article summarizes highlights from the 2024 AWS Life Sciences Leaders Symposium, which focused on how life sciences organizations can leverage generative AI, machine learning, and data analytics on AWS to revolutionize drug discovery and clinical development.

Specifically, the article covers:

• 2024 being declared the "Year of Production" for generative AI in life sciences, with 9 out of top 10 pharma companies using AWS for generative AI and machine learning
• Key considerations for moving generative AI from proof-of-concept to production, including extensibility, ability to deploy new workflows, and proprietary data management
• AWS's collaboration with NVIDIA and Genentech to streamline training and deployment of specialized models for drug discovery and development
• Real-world implementations of generative AI for drug discovery by startups like Terray Therapeutics and Vertex Pharmaceuticals
• AWS partner solutions for generative AI in R&D and clinical development from ZS and PwC
• Importance of robust data foundations and strategies, like Gilead's data mesh architecture, to enable innovation with generative AI
• Conclusion: The imperative for life sciences leaders to act now and leverage generative AI responsibly, with AWS's support